In May 2021, American Gene Technologies (AGT), a clinical-stage biotechnology company, announced the treatment of the first participant in its Phase I clinical trial to evaluate the safety of the cell and gene therapy product AGT103-T. Designated as the RePAIR trial (Restore Potent Antiviral Immune Responses, NCT04561258), participants are infused once with their own CD4 T cells that were enriched, for cells capable of reacting to HIV, and genetically modified to resist infection. This is a first-in-human study for AGT103-T. The primary endpoint is safety; testing related to secondary endpoints evaluates responses to treatment including changes in the immune response to HIV. This video explains AGT’s research and HIV cure program strategy.